Snoop Dogg’s Casa Verde Backs Record UK Cannabis Telemedicine Deal

Snoop Dogg is not only a hip-hop legend but also a seasoned businessman. Now, his fund, Casa Verde Capital, has invested £4.5 million in Mamedica, a leading British medical cannabis clinic. This is the largest transaction of its kind in British history. Let’s examine what this means for patients and the cannabis market as a whole.

Mamedica and Casa Verde Capital – who are the main players?

To understand the importance of this information, you need to understand both sides of the transaction. These are not just random companies.

Mamedica: a digital revolution in access to treatment

Mamedica is a modern clinic that operates entirely online. Launched in 2022, it quickly gained patient trust. Today, it cares for 7,500 people suffering from chronic and neurological conditions. The goal is to double that number this year.

How does it work? Patients consult with their doctor via video and receive their medications in a discreet package directly to their home. This model, called telemedicine , was also available in Poland until November 2023. The UK National Health Service (NHS) rarely reimburses cannabis treatments, citing a lack of sufficient scientific evidence.

Casa Verde: Snoop Dogg’s Fund with a Global Vision

Casa Verde Capital is a US-based investment fund that has backed over 100 cannabis companies since 2015. Its team doesn’t just provide funding; it also offers strategic support. In Mamedica’s case, Casa Verde experts Karan Wadhera and Tony Ghanem will help the clinic expand internationally, particularly in the North American market.

Record £4.5 million – what do we know about this investment?

The £4.5 million funding is the largest single round of funding for a cannabis telemedicine company in the UK. Interestingly, Snoop Dogg isn’t the only celebrity to have put his faith in Mamedica. Others participating in this funding round include:

Bobby Zamora and Mark Noble – former Premier League footballers.
Jay Rutland – famous entrepreneur and art dealer.

The presence of such names demonstrates that medical cannabis is no longer a niche topic. It is becoming a serious and promising sector of the economy.

The UK Medical Cannabis Market: Great Potential and Harsh Realities

Medical cannabis has been legal on prescription in the UK since 2018. The impetus for this change was a high-profile campaign on behalf of children with severe epilepsy. Today, the market is on track to reach £1 billion.

Forecasts are optimistic. Analysts at Grand View Research estimate that sector revenues will grow from $12.5 million last year to nearly $63 million in 2030. It is already predicted that up to 100,000 patients will benefit from the therapy this year.

The path to success, however, is not straightforward. Market regulators (MHRA) require hard evidence of treatment effectiveness. Private insurers are reluctant to cover costs, and cannabis therapies still account for less than 1% of the overall pain management market. Patient growth is steady but slow.

What does Snoop Dogg’s investment mean for patients?

Casa Verde’s investment is great news for patients. Most of the money will go towards:

Scientific research – to provide the evidence that regulators demand.
Expanding the offer – more specialists and therapeutic options.
Improving access – streamlining the online platform and logistics.

Snoop Dogg’s investment is also a signal to other companies. The telemedicine model is working and attracting major investors. Competition will have to catch up with Mamedica, which will ultimately improve the quality of services for all patients.

__

(Featured image by Clayton Cardinalli via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in FaktyKonopne. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.